Analysts Expect Celgene Co. (CELG) to Announce $2.31 EPS
Equities analysts predict that Celgene Co. (NASDAQ:CELG) will report earnings of $2.31 per share for the current quarter, according to Zacks. Eight analysts have issued estimates for Celgene’s earnings, with the highest EPS estimate coming in at $2.36 and the lowest estimate coming in at $2.26. Celgene reported earnings per share of $2.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.5%. The company is scheduled to report its next earnings results on Thursday, January 24th.
According to Zacks, analysts expect that Celgene will report full year earnings of $8.80 per share for the current financial year, with EPS estimates ranging from $8.75 to $8.84. For the next year, analysts expect that the company will post earnings of $10.48 per share, with EPS estimates ranging from $9.93 to $11.21. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Celgene.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.02 by $0.27. The firm had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%.
Shares of NASDAQ:CELG opened at $70.24 on Friday. The firm has a market capitalization of $49.66 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 0.44 and a beta of 1.53. Celgene has a 52 week low of $70.09 and a 52 week high of $110.81. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13.
A number of institutional investors have recently made changes to their positions in CELG. Ayalon Holdings Ltd. bought a new stake in shares of Celgene during the 2nd quarter valued at about $100,000. Atlantic Trust LLC bought a new stake in shares of Celgene during the 2nd quarter valued at about $101,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Celgene during the 3rd quarter valued at about $132,000. City Holding Co. bought a new stake in shares of Celgene during the 2nd quarter valued at about $143,000. Finally, Sun Life Financial INC boosted its stake in shares of Celgene by 528.9% during the 2nd quarter. Sun Life Financial INC now owns 1,918 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 1,613 shares in the last quarter. 73.72% of the stock is currently owned by institutional investors and hedge funds.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.